logo-loader
viewProactive Insights

IFG agrees to be taken out by UK private equity firm Epiris in £206mln deal

IFG bosses said the deal was a “compelling” exit opportunity for shareholders, who have been told to accept the offer

st paul's cathedral
IFG has more than £35bn of assets under administration or advice

Financial services firm IFG Group PLC (LON:IFG) has agreed to be taken out by London-based private equity firm Epiris in a deal worth £206mln.

Epiris, whose investments also include TGI Fridays, Hollywood Bowl and auction house Bonhams, is to pay 193p for each IFG share.

READ: Announcement in full

That offer represents a premium of 46% compared to the closing price of the stock on Friday afternoon and values IFG at 21.4 times earnings.

“We are pleased to be announcing this transaction today and believe it is an excellent outcome for shareholders, for the company, and for our clients,” said IFG chief executive Kathryn Purves.

“The offer by Epiris represents a compelling opportunity for shareholders to realise an immediate and attractive cash value for their shareholding in IFG today.”

Epiris’ Owen Wilson added: “We are delighted that the Board of IFG has recommended our offer and we are excited to work with management to realise the growth potential of James Hay and of Saunderson House and to further enhance their position in their respective markets.”

IFG had put its Sanderson House business on the chopping block early in 2018 after a strategy review concluded that its disposal might create greater value for shareholders.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sareum Holdings raises over a £1mln to advance preclinical work on its...

Sareum Holdings PLC's (LON:SAR) Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802. Mitchell says they're exploring the potential benefit of the TYK2/JAK1...

1 hour, 35 minutes ago

2 min read